Rhenium re-188

DB19267InvestigationalSmall molecule

Rhenium re-188 is under investigation in clinical trial NCT03458559 (Rhenium-188-hedp vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20, Receptor tyrosine-protein kinase erbB-2, and Protein-glutamine gamma-glutamyltransferase 2
Curator reviewed
Formula / weight: Re · 187.9581 g/mol (avg)
Also known as: Rhenium-188 · Rhenium, isotope of mass 188
Code names: 188RE · Re 188

Resolves to

Compound

UNII229C124H5ICAS14378-26-8

Structure

InChIKeyWUAPFZMCVAUBPE-NJFSPNSNSA-NSMILES[188Re]

Targets

P11836MS4A1P04626ERBB2P21980TGM2P00533EGFRP19320VCAM1

What you can answer from here — as of July 09, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rhenium re-188, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account